A PYMNTS Company

US: Sun Pharma enters settlement in antitrust litigation

 |  July 9, 2017

Indian pharmaceutical giant Sun Pharmaceutical Industries and one of its wholly-owned subsidiaries have entered into settlements with “certain plaintiffs” in an antitrust litigation matter currently pending in the United States, the company said.

“Sun Pharmaceutical Industries, and one of its wholly-owned subsidiaries have entered into settlements with certain plaintiffs in re Modafinil Antitrust Litigation matter currently pending in the United states District Court for the Eastern District of Pennsylvania,” the drug maker told the Bombay Stock Exchange late on Friday.

The settlements extend to all claims brought by Canadian pharma Apotex and the Retailer Purchaser Plaintiffs, the company said, adding that the terms of the settlements are confidential.

Full Content: India Today

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.